Identification

Name
Oxybutynin
Accession Number
DB01062  (APRD00427)
Type
Small Molecule
Groups
Approved, Investigational
Description

Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.

Structure
Thumb
Synonyms
  • 4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
  • 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
  • 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
  • Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
  • Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
  • Oxibutinina
  • Oxybutynin
  • Oxybutynine
  • Oxybutyninum
Product Ingredients
IngredientUNIICASInChI Key
Oxybutynin ChlorideL9F3D9RENQ1508-65-2SWIJYDAEGSIQPZ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albert OxybutyninTablet5 mgOralAventis Pharma Ltd.1996-11-212002-07-29Canada
Ava-oxybutyninTablet5 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ditropan Syrup 1mg/mlSyrup1 mgOralJanssen Pharmaceuticals1993-12-312007-02-21Canada
Ditropan Tablets 5mgTablet5 mgOralJanssen Pharmaceuticals1993-12-312006-08-04Canada
Ditropan XLTablet, extended release5 mg/1OralJanssen Pharmaceuticals1999-06-26Not applicableUs
Ditropan XLTablet, extended release15 mg/1OralJanssen Pharmaceuticals1999-06-26Not applicableUs
Ditropan XLTablet, extended release15 mgOralJanssen PharmaceuticalsNot applicableNot applicableCanada
Ditropan XLTablet, extended release15 mg/1OralPhysicians Total Care, Inc.2003-06-25Not applicableUs
Ditropan XLTablet, extended release10 mg/1OralJanssen Pharmaceuticals1999-06-26Not applicableUs
Ditropan XLTablet, extended release10 mg/1OralPhysicians Total Care, Inc.2003-06-23Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxybutyninSyrup5 mgOralApotex Corporation1997-04-28Not applicableCanada
Apo-oxybutynin - Tab 5mgTablet5 mgOralApotex Corporation1995-12-31Not applicableCanada
OxybutyninTablet, film coated, extended release15 mg/1OralCadila Pharnmaceuticals2017-08-10Not applicableUs
OxybutyninTablet, film coated, extended release15 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-10Not applicableUs
OxybutyninTablet, film coated, extended release10 mg/1OralCadila Pharnmaceuticals2017-08-10Not applicableUs
OxybutyninTablet, film coated, extended release10 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-10Not applicableUs
OxybutyninTablet, film coated, extended release5 mg/1OralCadila Pharnmaceuticals2017-08-10Not applicableUs
OxybutyninTablet, film coated, extended release5 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-10Not applicableUs
Oxybutynin ChlorideTablet, film coated, extended release10 mg/1OralPhysicians Total Care, Inc.2006-12-12Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralCardinal Health2011-11-072017-05-10Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxytrol For WomenPatch3.9 mg/dTransdermalActavis Pharma Company2016-01-01Not applicableUs
Oxytrol For WomenPatch3.9 mg/dTransdermalMsd Consumer Care Inc.2013-08-192017-11-09Us
Oxytrol For WomenPatch3.9 mg/dTransdermalMsd Consumer Care Inc.2013-08-192017-11-09Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxybutynin ChlorideTablet5 mg/1OralRemedy Repack2017-11-17Not applicableUs
Oxybutynin ChlorideTablet5 mg/1OralNovitium Pharma Llc2017-11-15Not applicableUs
OxytrolPatch3.9 mg/dTransdermalAllergan2003-02-26Not applicableUs
International/Other Brands
Ditropan / Lenditro / Lyrinel XL
Categories
UNII
K9P6MC7092
CAS number
5633-20-5
Weight
Average: 357.4864
Monoisotopic: 357.230393863
Chemical Formula
C22H31NO3
InChI Key
XIQVNETUBQGFHX-UHFFFAOYSA-N
InChI
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
IUPAC Name
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
SMILES
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of overactive bladder.

Structured Indications
Pharmacodynamics

Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.

Mechanism of action

Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption

Rapidly absorbed from gastrointestinal tract.

Volume of distribution
  • 193 L
Protein binding

91%-93%

Metabolism

Hepatic, primarily by CYP3A4

Route of elimination

Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.

Half life

12.4-13.2 hours

Clearance

Estimated to be 26L/h.

Toxicity

LD50=1220 mg/kg (Orally in rats, Goldenthal)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumOxybutynin may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Oxybutynin.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxybutynin.Approved
AprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Oxybutynin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Atorvastatin.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxybutynin.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxybutynin.Approved
BezitramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.Approved, Investigational
BoceprevirThe serum concentration of Oxybutynin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Oxybutynin.Experimental
BortezomibThe metabolism of Oxybutynin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Oxybutynin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Oxybutynin.Approved
Botulinum Toxin Type AOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxybutynin.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Scopolamine butylbromide.Approved, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Oxybutynin.Approved
CarbamazepineThe metabolism of Oxybutynin can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Carfentanil.Illicit, Investigational, Vet Approved
CeritinibThe serum concentration of Oxybutynin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Oxybutynin.Withdrawn
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.Approved
CimetropiumOxybutynin may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClarithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Oxybutynin can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Oxybutynin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Oxybutynin can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Oxybutynin can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Oxybutynin can be decreased when combined with Crizotinib.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Oxybutynin.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.Approved
CyclosporineThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin.Approved, Investigational
DarunavirThe serum concentration of Oxybutynin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Oxybutynin can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Oxybutynin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Oxybutynin can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxybutynin.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Oxybutynin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Oxybutynin.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Oxybutynin.Experimental
DihydroergotamineThe metabolism of Oxybutynin can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Oxybutynin can be decreased when combined with Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Donepezil.Approved
DoxycyclineThe metabolism of Oxybutynin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxybutynin is combined with DPDPE.Experimental
DronabinolOxybutynin may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Oxybutynin can be decreased when combined with Dronedarone.Approved
EchothiophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Edrophonium.Approved
EluxadolineOxybutynin may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Emepronium.Experimental
EnzalutamideThe serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Oxybutynin.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Oxybutynin.Approved
ErythromycinThe metabolism of Oxybutynin can be decreased when combined with Erythromycin.Approved, Vet Approved
EtanautineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etanautine.Experimental
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxybutynin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.Approved
FluconazoleThe metabolism of Oxybutynin can be decreased when combined with Fluconazole.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Oxybutynin.Approved
FluvoxamineThe metabolism of Oxybutynin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Oxybutynin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Oxybutynin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxybutynin can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Oxybutynin can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxybutynin.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.Approved
GlycopyrroniumOxybutynin may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.Approved
IdelalisibThe serum concentration of Oxybutynin can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Oxybutynin can be decreased when combined with Imatinib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.Approved
IndinavirThe serum concentration of Oxybutynin can be increased when it is combined with Indinavir.Approved
IpidacrineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.Approved
IsavuconazoniumThe metabolism of Oxybutynin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsradipineThe metabolism of Oxybutynin can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Oxybutynin.Investigational
ItraconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Oxybutynin can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Ketoconazole.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levorphanol.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Oxybutynin.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Oxybutynin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Oxybutynin can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Oxybutynin.Illicit, Investigational, Withdrawn
MalathionThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.Approved
MefloquineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Meptazinol.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Oxybutynin.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxybutynin.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Oxybutynin.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methylscopolamine bromide.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Oxybutynin.Approved
MetixeneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Oxybutynin.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Oxybutynin.Experimental
MianserinMianserin may increase the anticholinergic activities of Oxybutynin.Approved, Investigational
MifepristoneThe serum concentration of Oxybutynin can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.Approved
MitotaneThe serum concentration of Oxybutynin can be decreased when it is combined with Mitotane.Approved
MorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.Approved, Investigational
NabiloneOxybutynin may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.Approved
NefazodoneThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Oxybutynin can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Oxybutynin can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Oxybutynin.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Nicomorphine.Experimental
NilotinibThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Normethadone.Approved, Illicit
OlaparibThe metabolism of Oxybutynin can be decreased when combined with Olaparib.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Oxybutynin can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxitropium.Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxybutynin.Approved
PalbociclibThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Oxybutynin can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentolinium.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Oxybutynin.Approved, Investigational, Vet Approved, Withdrawn
PethidineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxybutynin.Experimental
PhenobarbitalThe metabolism of Oxybutynin can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Phenoperidine.Experimental
PhenytoinThe metabolism of Oxybutynin can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.Approved
PiritramideThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Oxybutynin.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Oxybutynin.Approved
PosaconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideOxybutynin may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Oxybutynin.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Oxybutynin.Approved
PrimidoneThe metabolism of Oxybutynin can be increased when combined with Primidone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxybutynin.Approved
PropiverineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Propiverine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxybutynin.Approved
RamosetronOxybutynin may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Oxybutynin can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.Approved
RifabutinThe metabolism of Oxybutynin can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Oxybutynin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxybutynin can be increased when combined with Rifapentine.Approved
RivastigmineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Rivastigmine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Oxybutynin.Approved
SaquinavirThe serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxybutynin.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.Approved, Investigational
SildenafilThe metabolism of Oxybutynin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Oxybutynin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Oxybutynin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Oxybutynin.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Solifenacin.Approved
St. John's WortThe serum concentration of Oxybutynin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Oxybutynin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Oxybutynin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Oxybutynin.Approved, Investigational
TacrineThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.Approved
TelaprevirThe serum concentration of Oxybutynin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Oxybutynin can be increased when it is combined with Telithromycin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Oxybutynin.Experimental
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxybutynin.Approved, Withdrawn
TiclopidineThe metabolism of Oxybutynin can be decreased when combined with Ticlopidine.Approved
TilidineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tilidine.Experimental
TiotropiumOxybutynin may increase the anticholinergic activities of Tiotropium.Approved
TocilizumabThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxybutynin.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxybutynin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxybutynin.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Oxybutynin.Approved, Investigational, Nutraceutical
UmeclidiniumOxybutynin may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Oxybutynin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Oxybutynin can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Oxybutynin can be increased when it is combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Oxybutynin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Masakatsu Shibasaki, "Method of producing oxybutynin and its derivatives." U.S. Patent US20040006243, issued January 08, 2004.

US20040006243
General References
  1. Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. [PubMed:16924061]
  2. Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. [PubMed:17057269]
  3. Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. [PubMed:17438194]
External Links
Human Metabolome Database
HMDB15195
KEGG Drug
D00465
KEGG Compound
C07360
PubChem Compound
4634
PubChem Substance
46508005
ChemSpider
4473
BindingDB
50165019
ChEBI
7856
ChEMBL
CHEMBL1231
Therapeutic Targets Database
DAP001128
PharmGKB
PA164746030
IUPHAR
359
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Oxybutynin
ATC Codes
G04BD04 — Oxybutynin
AHFS Codes
  • 86:12.04 — Antimuscarinics
FDA label
Download (144 KB)
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingOtherHeat Effect1
1CompletedNot AvailableHealthy Volunteers6
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentOveractive Bladder1
1, 2RecruitingTreatmentObstructive Sleep Apnea (OSA)1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentMenopausal Hot Flushes / Menopause1
2CompletedTreatmentPost-nasal Drip / Rhinorrhea / Seasonal Allergic Rhinitis (SAR)1
2CompletedTreatmentUrinary Incontinence, Urge1
2Not Yet RecruitingTreatmentSpinal Cord Injuries (SCI) / Urinary Bladder, Neurogenic1
2RecruitingOtherMild Cognitive Impairment (MCI) / Overactive Bladder1
3CompletedPreventionNeurogenic Bladder Dysfunction1
3CompletedTreatmentHyperhidrosis1
3CompletedTreatmentNocturnal Enuresis1
3CompletedTreatmentOveractive Bladder1
3CompletedTreatmentUrge Urinary Incontinence / Urinary Frequency1
3CompletedTreatmentUrinary Incontinence (UI)2
3CompletedTreatmentUrination Disorders1
3Enrolling by InvitationTreatmentOveractive Bladder1
3RecruitingSupportive CareBothered by Hot Flashes / Carcinoma, Breast / Ductal Breast Carcinoma In Situ / Lobular Breast Carcinoma In Situ / Menopausal Hot Flushes / No Evidence of Disease1
3RecruitingTreatmentDiabetic; Neuropathic, Polyneuropathy (Manifestation)1
3RecruitingTreatmentOveractive Bladder1
3RecruitingTreatmentUrinary Bladder, Neurogenic1
3WithdrawnTreatmentHyperhidrosis1
4CompletedNot AvailableCognition1
4CompletedTreatmentCognition / Memory1
4CompletedTreatmentDetrusor Hyperreflexia2
4CompletedTreatmentHyperhidrosis1
4CompletedTreatmentNeurogenic Detrusor Overactivity / Spinal Cord Injuries (SCI)1
4CompletedTreatmentOveractive Bladder2
4CompletedTreatmentUrinary Incontinence Mixed (Stress and Urge)1
4RecruitingTreatmentNeurogenic Bladder Dysfunction / Overactive Detrusor1
4TerminatedTreatmentUrinary Urge Incontinence1
4Unknown StatusTreatmentOveractive Bladder1
Not AvailableActive Not RecruitingTreatmentHyperhidrosis1
Not AvailableCompletedNot AvailableHyperhidrosis1
Not AvailableCompletedNot AvailableOveractive Bladder / Urinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases1
Not AvailableCompletedTreatmentAxillary Hyperhidrosis / Osmidrosis1
Not AvailableCompletedTreatmentHyperhidrosis1
Not AvailableCompletedTreatmentOveractive Bladder / Parkinson's Disease (PD)1
Not AvailableCompletedTreatmentSpinal Cord Injuries (SCI)1
Not AvailableCompletedTreatmentUrinary Incontinence (UI)1
Not AvailableCompletedTreatmentUrinary Incontinence, Urge1
Not AvailableNot Yet RecruitingDiagnosticOveractive Bladder1
Not AvailableNot Yet RecruitingTreatmentDisorder of Urinary Stent1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
SyrupOral1 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral5 mg
GelTopical10 %
GelTopical100 mg
GelTransdermal100 mg/g
GelTransdermal28 mg/.92g
GelTransdermal90.7 mg/g
PatchTransdermal3.9 mg/24h
Tablet, film coated, extended releaseOral15 mg/1
SolutionOral5 mg/5mL
SyrupOral5 mg/5mL
TabletOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral5 mg/1
PatchTransdermal3.9 mg
PatchTransdermal3.9 mg/d
SyrupOral5 mg
TabletOral2.5 mg
Tablet, extended releaseOral15 mg
Prices
Unit descriptionCostUnit
Oxybutynin chloride powder54.47USD g
Oxytrol 3.9 mg/24hr Patches20.87USD patch
Oxytrol 3.9 mg/24hr patch20.06USD patch
Gelnique 10% gel sachets5.17USD g
Ditropan XL 15 mg 24 Hour tablet4.59USD tablet
Ditropan XL 10 mg 24 Hour tablet4.47USD tablet
Ditropan XL 5 mg 24 Hour tablet4.47USD tablet
Ditropan xl 15 mg tablet4.23USD tablet
Ditropan xl 10 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet4.13USD tablet
Ditropan xl 5 mg tablet sa4.13USD tablet
Oxybutynin Chloride 15 mg 24 Hour tablet3.5USD tablet
Oxybutynin Chloride 10 mg 24 Hour tablet3.42USD tablet
Oxybutynin Chloride 5 mg 24 Hour tablet3.2USD tablet
Ditropan 5 mg tablet1.15USD tablet
Oxybutynin Chloride 5 mg tablet0.57USD tablet
Ditropan 5 mg/5ml Syrup0.26USD ml
Apo-Oxybutynin 5 mg Tablet0.26USD tablet
Mylan-Oxybutynin 5 mg Tablet0.26USD tablet
Novo-Oxybutynin 5 mg Tablet0.26USD tablet
Nu-Oxybutyn 5 mg Tablet0.26USD tablet
Pms-Oxybutynin 5 mg Tablet0.26USD tablet
Oxybutynin Chloride 5 mg/5ml Syrup0.21USD ml
Oxybutynin 5 mg tablet0.17USD tablet
Pms-Oxybutynin 2.5 mg Tablet0.14USD tablet
Pms-Oxybutynin 1 mg/ml Syrup0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164190No1993-12-112010-12-11Us
CA2218714No2005-08-232016-05-08Canada
US6743441No2000-04-262020-04-26Us
US7081249No2000-04-262020-04-26Us
US7081250No2000-04-262020-04-26Us
US7081251No2000-04-262020-04-26Us
US7081252No2000-04-262020-04-26Us
US7179483No2000-04-262020-04-26Us
US7198801No2002-06-252022-06-25Us
US7029694No2000-04-262020-04-26Us
US8241662No2000-04-262020-04-26Us
US8920392No2011-03-262031-03-26Us
US9259388No2009-11-062029-11-06Us
US6262115Yes1995-11-222015-11-22Us
US5912268Yes1995-11-222015-11-22Us
US5840754Yes1995-11-222015-11-22Us
US5674895Yes1995-11-222015-11-22Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)129-130 °CNot Available
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP4.36ALOGPS
logP4.44ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)11.53ChemAxon
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity105.26 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9225
Blood Brain Barrier+0.9418
Caco-2 permeable+0.5989
P-glycoprotein substrateSubstrate0.7244
P-glycoprotein inhibitor IInhibitor0.6809
P-glycoprotein inhibitor IIInhibitor0.7244
Renal organic cation transporterNon-inhibitor0.558
CYP450 2C9 substrateNon-substrate0.812
CYP450 2D6 substrateNon-substrate0.7985
CYP450 3A4 substrateNon-substrate0.5213
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7137
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7038
BiodegradationNot ready biodegradable0.9878
Rat acute toxicity2.9059 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Inhibitor0.7337
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0009000000-ca7fded3c414981568e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-6809000000-96b23747cce7288ac89a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0597-9700000000-d3a66f5713202ca9c1a4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abc-9500000000-71ea5dc94f4b2826c6ab
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0abc-9400000000-4fd7390913d44a84a47e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0adi-9200000000-4ee96335c41ac4541fdd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0009000000-1db2750867b2b3a978a6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-1309000000-8015ca27a0f3148e2038
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0596-8900000000-c19752bfc85d658650c9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0abc-9600000000-2ba4db19cf29c878577a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0adl-9300000000-79de4e5ce2d791c91567
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0239000000-ae8df1c9b5ec536100dd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1529000000-23d56124ac4d3f859ebe
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-8609000000-b2a50c9ada94fb87686a

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Tertiary alcohols / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Monocyclic benzene moiety / Tertiary alcohol / Amino acid or derivatives / Carboxylic acid ester / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Alcohol / Aromatic alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary alcohol, tertiary amine, acetate ester, acetylenic compound (CHEBI:7856)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Baldwin CM, Keating GM: Transdermal oxybutynin. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. [PubMed:19275276]
  4. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545]
  5. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605]
  6. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678]
  7. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Dmochowski R: Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf. 2005;28(7):583-600. [PubMed:15963006]
  2. Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27. [PubMed:16188951]
  3. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13. [PubMed:19446545]
  4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605]
  5. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x. [PubMed:20590605]
  4. Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70. [PubMed:17222678]
  5. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9. [PubMed:16406943]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Yaich M, Popon M, Medard Y, Aigrain EJ: In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998 Oct;8(5):449-51. [PubMed:9825837]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18